The carcinoid syndrome drug market is experiencing steady growth due to the increasing incidence of neuroendocrine tumors (NETs) and advancements in targeted therapies. Carcinoid syndrome is a rare condition caused by hormone-secreting carcinoid tumors, leading to symptoms like flushing, diarrhea, wheezing, and heart complications. Treatment includes somatostatin analogs (SSAs), targeted...